Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

Rhea-AI Summary

Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will participate in the Advances in Neuropsychiatry Panel on April 29, 2021, at 10:30 AM ET. The panel is part of the Annual Neuroscience Innovation Forum taking place from April 28-30, 2021. A video of the company's presentation is available on-demand and will remain accessible until May 26, 2021. Vallon's lead product candidate is ADAIR, an abuse-deterrent formulation of amphetamine for treating ADHD and narcolepsy.

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29^th at 10:30 AM ET

PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will participate at the virtual 4^th Annual Neuroscience Innovation Forum being held April 28-30, 2021.

A video webcast of the Company’s presentation is now available on-demand in the Showcase section of the conference portal and will be accessible on the conference platform until May 26, 2021. Following the event, the presentation will be made available on the Company’s website.

Additionally, Mr. Baker will be a panelist on the virtual Advances in Neuropsychiatry Panel, being held on April 29, 2021 at 10:30 AM ET. The live webcast of the panel will be accessible to those registered to attend the conference.

Management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the conference one-on-one desk or reach out through the online platform.

For more information about the event, please visit the conference website.

About Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

For more information about the company, please visit www.vallon-pharma.com.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

FAQ

What event will David Baker participate in for Vallon Pharmaceuticals on April 29, 2021?

David Baker will participate in the Advances in Neuropsychiatry Panel on April 29, 2021.

What is Vallon Pharmaceuticals' lead product candidate?

Vallon's lead product candidate is ADAIR, an abuse-deterrent formulation of amphetamine.

When is the Annual Neuroscience Innovation Forum 2021?

The Annual Neuroscience Innovation Forum is taking place from April 28 to April 30, 2021.

How can I access Vallon's presentation from the conference?

Vallon's presentation is available on-demand until May 26, 2021, via the conference portal.

What is the focus of Vallon Pharmaceuticals?

Vallon Pharmaceuticals focuses on developing novel drugs to deter abuse in the treatment of CNS disorders.